SCHEMBL20186697

SCHEMBL20186697

CCS(=O)(=O)Nc1cc(C(=O)OC)cc(Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.51
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 6/20 0.49
MAPT P10636 1/20 0.49
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ACLY P53396 1/20 0.39
GPR119 Q8TDV5 3/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2257869 0.85 POLB (0.48) HPGDALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL22999837 0.79 HPGD (0.52) HPGDALDH1A1KDM4EMAPTGPR119
SCHEMBL569249 0.79 ALDH1A1 (0.59) HPGDALDH1A1KDM4EMAPTTSHR
SCHEMBL3854836 0.78 ALDH1A1 (0.43) ALDH1A1KDM4ECYP1A2TSHRCYP2C19
SCHEMBL3715743 0.78 ALDH1A1 (0.50) HPGDALDH1A1KDM4EMAPTTSHR
Hydrochloric Acid SCHEMBL29890892 0.77 ALDH1A1 (0.57) HPGDALDH1A1KDM4EMAPTTSHR
SCHEMBL3853514 0.75 HCAR3 (0.43) ALDH1A1KDM4ECA12CA1CA2
SCHEMBL3853513 0.75 HCAR3 (0.43) ALDH1A1KDM4ECA12CA1CA2
SCHEMBL21158928 0.75 ALDH1A1 (0.48) HPGDALDH1A1KDM4EMAPTCYP1A2
SCHEMBL475759 0.74 HPGD (0.70) HPGDALDH1A1KDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3548495-B1 PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS GILEAD SCIENCES INC (US) 2021-01-27 EP disclosed
US-10100058-B2 Fused heterocyclic compounds as CaM kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-10-16 US disclosed
US-20180148457-A1 FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS GILEAD SCIENCES, INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10100058-B2 Fused heterocyclic compounds as CaM kinase inhibitors CAMK1, CAMKK1, CAMK1D HPGD 1387/4885ALDH1A1 1512/4885KDM4E 2635/4885
US-20180148457-A1 FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS CAMK1, CAMKK1, CAMK1D HPGD 1387/4885ALDH1A1 1512/4885KDM4E 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.